Enzymotec (NASDAQ: ENZY) and Ingevity (NYSE:NGVT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Insider and Institutional Ownership
15.7% of Enzymotec shares are owned by institutional investors. Comparatively, 91.1% of Ingevity shares are owned by institutional investors. 0.1% of Ingevity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations for Enzymotec and Ingevity, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Enzymotec presently has a consensus price target of $11.75, suggesting a potential downside of 0.84%. Ingevity has a consensus price target of $79.20, suggesting a potential upside of 12.39%. Given Ingevity’s stronger consensus rating and higher probable upside, analysts plainly believe Ingevity is more favorable than Enzymotec.
Risk & Volatility
Enzymotec has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Ingevity has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.
This table compares Enzymotec and Ingevity’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Enzymotec and Ingevity’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Enzymotec||$47.70 million||5.82||-$2.92 million||($0.26)||-45.58|
|Ingevity||$908.30 million||3.27||$35.20 million||$2.22||31.74|
Ingevity has higher revenue and earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than Ingevity, indicating that it is currently the more affordable of the two stocks.
Ingevity beats Enzymotec on 12 of the 13 factors compared between the two stocks.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Ingevity Corporation is a manufacturer of specialty chemicals and high performance carbon materials. The Company is also a manufacturer of activated carbon used in gasoline vapor emission control systems in cars, trucks, motorcycles and boats. The Company operates through two segments: Performance Materials and Performance Chemicals. The Performance Materials segment primarily produces automotive carbon products used in gasoline vapor emission control systems in cars, trucks, motorcycles and boats. The Performance Chemicals segment develops, manufactures and sells a range of specialty chemicals primarily derived from co-products of the Kraft pulping process. Its products are used in a range of applications, including asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, publication inks and automotive components that reduce gasoline vapor emissions.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.